Cargando…

Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China

PURPOSE: To evaluate the oncologic efficacy and feasibility of nephron-sparing surgery (NSS) in adult Xp11.2 translocation renal cell carcinoma (RCC). PATIENTS AND METHODS: Seventy patients with Xp11.2 translocation RCC and 273 with conventional RCC from five institutions in Nanjing were retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ning, Qu, Feng, Shi, Qiancheng, Zhuang, Wenyuan, Ma, Wenliang, Yang, Zhenhao, Sun, Jing, Xu, Wei, Zhang, Lihua, Jia, Ruipeng, Xu, Linfeng, Zhao, Xiaozhi, Li, Xiaogong, Zhang, Gutian, Guo, Hongqian, Li, Dongmei, Gan, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801353/
https://www.ncbi.nlm.nih.gov/pubmed/32632879
http://dx.doi.org/10.1245/s10434-020-08813-y
_version_ 1783635554813870080
author Liu, Ning
Qu, Feng
Shi, Qiancheng
Zhuang, Wenyuan
Ma, Wenliang
Yang, Zhenhao
Sun, Jing
Xu, Wei
Zhang, Lihua
Jia, Ruipeng
Xu, Linfeng
Zhao, Xiaozhi
Li, Xiaogong
Zhang, Gutian
Guo, Hongqian
Li, Dongmei
Gan, Weidong
author_facet Liu, Ning
Qu, Feng
Shi, Qiancheng
Zhuang, Wenyuan
Ma, Wenliang
Yang, Zhenhao
Sun, Jing
Xu, Wei
Zhang, Lihua
Jia, Ruipeng
Xu, Linfeng
Zhao, Xiaozhi
Li, Xiaogong
Zhang, Gutian
Guo, Hongqian
Li, Dongmei
Gan, Weidong
author_sort Liu, Ning
collection PubMed
description PURPOSE: To evaluate the oncologic efficacy and feasibility of nephron-sparing surgery (NSS) in adult Xp11.2 translocation renal cell carcinoma (RCC). PATIENTS AND METHODS: Seventy patients with Xp11.2 translocation RCC and 273 with conventional RCC from five institutions in Nanjing were retrospectively studied. All patients were older than 18 years and were categorized into clinical T1 (cT1) stage using preoperative imaging. Using the preoperative imaging and electronic medical records, anatomical and pathological features were collected and analyzed. RESULTS: Among patients with Xp11.2 translocation RCC, 18/36 (50.0%) with cT1a and 12/34 (35.3%) with cT1b tumors underwent NSS. The respective proportions in the conventional RCC group were 121/145 (83.4%) and 93/128 (72.7%). Among cT1a tumors, the Xp11.2 translocation RCCs tended to be adjacent to the collecting system, sinus, and axial renal midline compared with conventional RCCs. Patients with Xp11.2 translocation RCCs who underwent NSS had comparable progression-free survival (PFS) and overall survival to radical nephrectomy (RN) patients (P > 0.05). Among cT1b tumors, surgical margin positivity and pelvicalyceal, vascular, and region lymphatic involvement were more likely to occur in the Xp11.2 translocation RCCs (P < 0.05). Patients with Xp11.2 translocation RCC who underwent RN had a more favorable PFS than those who underwent NSS (P = 0.048). However, multivariate analysis of PFS did not identify surgical method as a risk factor (P = 0.089). CONCLUSIONS: Among adults with Xp11.2 translocation RCC, NSS can be an alternative for patients with cT1a tumor but should be performed with more deliberation in patients with cT1b tumors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-020-08813-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7801353
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78013532021-01-21 Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China Liu, Ning Qu, Feng Shi, Qiancheng Zhuang, Wenyuan Ma, Wenliang Yang, Zhenhao Sun, Jing Xu, Wei Zhang, Lihua Jia, Ruipeng Xu, Linfeng Zhao, Xiaozhi Li, Xiaogong Zhang, Gutian Guo, Hongqian Li, Dongmei Gan, Weidong Ann Surg Oncol Urologic Oncology PURPOSE: To evaluate the oncologic efficacy and feasibility of nephron-sparing surgery (NSS) in adult Xp11.2 translocation renal cell carcinoma (RCC). PATIENTS AND METHODS: Seventy patients with Xp11.2 translocation RCC and 273 with conventional RCC from five institutions in Nanjing were retrospectively studied. All patients were older than 18 years and were categorized into clinical T1 (cT1) stage using preoperative imaging. Using the preoperative imaging and electronic medical records, anatomical and pathological features were collected and analyzed. RESULTS: Among patients with Xp11.2 translocation RCC, 18/36 (50.0%) with cT1a and 12/34 (35.3%) with cT1b tumors underwent NSS. The respective proportions in the conventional RCC group were 121/145 (83.4%) and 93/128 (72.7%). Among cT1a tumors, the Xp11.2 translocation RCCs tended to be adjacent to the collecting system, sinus, and axial renal midline compared with conventional RCCs. Patients with Xp11.2 translocation RCCs who underwent NSS had comparable progression-free survival (PFS) and overall survival to radical nephrectomy (RN) patients (P > 0.05). Among cT1b tumors, surgical margin positivity and pelvicalyceal, vascular, and region lymphatic involvement were more likely to occur in the Xp11.2 translocation RCCs (P < 0.05). Patients with Xp11.2 translocation RCC who underwent RN had a more favorable PFS than those who underwent NSS (P = 0.048). However, multivariate analysis of PFS did not identify surgical method as a risk factor (P = 0.089). CONCLUSIONS: Among adults with Xp11.2 translocation RCC, NSS can be an alternative for patients with cT1a tumor but should be performed with more deliberation in patients with cT1b tumors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-020-08813-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-07-06 2021 /pmc/articles/PMC7801353/ /pubmed/32632879 http://dx.doi.org/10.1245/s10434-020-08813-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Urologic Oncology
Liu, Ning
Qu, Feng
Shi, Qiancheng
Zhuang, Wenyuan
Ma, Wenliang
Yang, Zhenhao
Sun, Jing
Xu, Wei
Zhang, Lihua
Jia, Ruipeng
Xu, Linfeng
Zhao, Xiaozhi
Li, Xiaogong
Zhang, Gutian
Guo, Hongqian
Li, Dongmei
Gan, Weidong
Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China
title Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China
title_full Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China
title_fullStr Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China
title_full_unstemmed Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China
title_short Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China
title_sort nephron-sparing surgery for adult xp11.2 translocation renal cell carcinoma at clinical t1 stage: a multicenter study in china
topic Urologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801353/
https://www.ncbi.nlm.nih.gov/pubmed/32632879
http://dx.doi.org/10.1245/s10434-020-08813-y
work_keys_str_mv AT liuning nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT qufeng nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT shiqiancheng nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT zhuangwenyuan nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT mawenliang nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT yangzhenhao nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT sunjing nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT xuwei nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT zhanglihua nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT jiaruipeng nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT xulinfeng nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT zhaoxiaozhi nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT lixiaogong nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT zhanggutian nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT guohongqian nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT lidongmei nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina
AT ganweidong nephronsparingsurgeryforadultxp112translocationrenalcellcarcinomaatclinicalt1stageamulticenterstudyinchina